Cardinal Capital Management Has $3.09 Million Stake in Masimo Co. (NASDAQ:MASI)

Cardinal Capital Management raised its position in Masimo Co. (NASDAQ:MASI) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,720 shares of the medical equipment provider’s stock after acquiring an additional 203 shares during the quarter. Cardinal Capital Management’s holdings in Masimo were worth $3,094,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MASI. NBC Securities Inc. lifted its stake in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the last quarter. UMB Bank n.a. raised its stake in Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares during the period. Trust Co. of Vermont acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $33,000. Blue Trust Inc. boosted its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 71 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Masimo by 136.5% during the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 269 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Price Performance

Shares of Masimo stock opened at $181.31 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $9.71 billion, a price-to-earnings ratio of 125.04 and a beta of 1.02. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $183.14. The company has a 50-day simple moving average of $172.65 and a two-hundred day simple moving average of $150.39.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Wells Fargo & Company raised their price objective on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.